Proton Laboratories, Inc./RegenoBody CEO Announces Strategic Milestones are on Track

Proton Laboratories, Inc./RegenoBody CEO Announces Strategic Milestones are on Track
SOSUA BAY, Dominican Republic, Jul 23, 2010 (GlobeNewswire via COMTEX) -- Proton Laboratories, Inc. (Pink Sheets:PLBI) CEO, Armando Casciati, announced today that the strategic milestones set for PLBI are on track and coming to fruition. During a statement made today, Mr. Casciati stated, "We believe our Company is fulfilling its obligations and milestones set to increase stockholder wealth with the construction of the clinic. Although we were held back by the restructuring of the convertible shares and compiling required information for Pink OTC Markets information reports, we are building upon all aspects of the company including:


  --  PLBI/RegenoBody's stem cell technology patent purchase for $2 Million
      Dollars including the rights to South America, the Caribbean and Mexico;
  --  PLBI/RegenoBody Investment in the clinic with the hiring of Dr.
      Keunmyuong Lee to supervise the installation;
  --  PLBI/RegenoBody payment of the first two installments on the clean lab;
  --  PLBI/RegenoBody expects the lab to be completed and the Company
      operational by early September based on promises from its laboratory
      equipment and set up supplier;
  --  The company is now on track to accomplish its goals of helping build a
      better life for its clients and families in need. With almost 3 Million
      dollars invested to date, PLBI/RegenoBody is determined to become
      Southern Hemisphere's leader in non-invasive, non-controversial stem
      cell technology and treatment.

 

 


About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A:

RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most potent cells in the world today. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technologic methods. The transplant physicians and stem cell laboratory scientists, associated with RNL Bio have been regarded as some of the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments will be delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.

About RNL Bio Company LTD:

RNL Bio is a premier biopharmaceutical company focused on development and commercialization of adult stem cell therapeutics and dog cloning technology. Headquartered in Seoul with a state-of-the-art GMP facility, RNL is a publicly traded company on the Korea Exchange (Code 003190) and strives to become a global leader across the biomedical industry.

FORWARD-LOOKING STATEMENT:

This report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this report are made as of the date hereof and the company undertakes no obligation to update such statements.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Proton Laboratories, Inc.

CONTACT:  Proton Laboratories, Inc.
Investor Relations
Tyler Cornell
[email protected]


 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.